PDF(Pubmed)
Abstract：
Taxane-related cystoid macular edema (CME) is a rare complication of the taxoid medication, a chemotherapeutic drug. We report a 47-year-old Han Chinese man referred to our Eye Center for decreased vision with visual distortion in both eyes for two weeks. Two weeks prior, he received the last cycle of his six-monthly chemotherapy, including paclitaxel for hypopharyngeal malignancy. The best-corrected visual acuity (BCVA) was 0.4 OD and 0.1 OS. Macular optical coherence tomography showed significant bilateral CME, and fluorescein angiography (FA) revealed the fluorescein pooling at the late phase without leakage. Intravitreal 700 μg dexamethasone (DEX) implant was applied to the left eye and 13 days after to the right eye. Two months later, the macular morphology recovered to normal. One year after the first visit, the BCVA was 1.0 OD and 0.8 OS with standard macula on OCT. In conclusion, the intravitreal DEX implant might be an effective adjuvant treatment for taxane-related CME.
摘要：
紫杉烷相关性黄斑囊样水肿（CME）是紫杉烷类药物的罕见并发症，化疗药物.我们报告了一名47岁的汉族男子，他将我们的眼科中心转诊为视力下降，双眼视觉畸变持续两周。两周前,他接受了六个月化疗的最后一个周期，包括用于下咽恶性肿瘤的紫杉醇。最佳矫正视力（BCVA）为0.4OD和0.1OS。黄斑光学相干断层扫描显示显著的双侧CME，荧光素血管造影术（FA）显示荧光素在晚期聚集而无泄漏。玻璃体内注射700μg地塞米松(DEX)植入物施用于左眼,13天后施用于右眼。两个月后,黄斑形态恢复正常。第一次访问一年后，在OCT上，BCVA为1.0OD和0.8OS，标准黄斑。总之,玻璃体内DEX植入可能是紫杉烷相关CME的有效辅助治疗.
